ATE322283T1 - Transdermale verwendung von sekretin zur behandlung von autismus - Google Patents

Transdermale verwendung von sekretin zur behandlung von autismus

Info

Publication number: ATE322283T1
Authority: AT; Austria
Prior art keywords: secretin; ferring; compositions; dmso; effective amount
Prior art date: 1998-06-09

Application number

AT99927416T

Other languages

English (en)

Inventor

Victoria Beck

Bernard Rimland

Original Assignee

Repligen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-09

Filing date

1999-06-09

Publication date

2006-04-15

1999-06-09 Application filed by Repligen Corp filed Critical Repligen Corp

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322283T1 publication Critical patent/ATE322283T1/de

Links

OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 abstract 11
102100037505 Secretin Human genes 0.000 abstract 8
108010086019 Secretin Proteins 0.000 abstract 8
229960002101 secretin Drugs 0.000 abstract 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
206010003805 Autism Diseases 0.000 abstract 1
208000020706 Autistic disease Diseases 0.000 abstract 1
-1 Secretin-Ferring Chemical compound 0.000 abstract 1
239000000443 aerosol Substances 0.000 abstract 1
230000003542 behavioural effect Effects 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
239000000499 gel Substances 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
239000006210 lotion Substances 0.000 abstract 1
239000007937 lozenge Substances 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
230000037368 penetrate the skin Effects 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000000829 suppository Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99927416T 1998-06-09 1999-06-09 Transdermale verwendung von sekretin zur behandlung von autismus ATE322283T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8857598P	1998-06-09	1998-06-09
US09/229,208 US6197746B1 (en)	1998-05-19	1999-01-13	Method of using secretin for treating autism

Publications (1)

Publication Number	Publication Date
ATE322283T1 true ATE322283T1 (de)	2006-04-15

Family

ID=26778819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99927416T ATE322283T1 (de)	1998-06-09	1999-06-09	Transdermale verwendung von sekretin zur behandlung von autismus

Country Status (8)

Country	Link
US (3)	US6197746B1 (de)
EP (1)	EP1085901B1 (de)
JP (1)	JP2002517467A (de)
AT (1)	ATE322283T1 (de)
AU (1)	AU772911B2 (de)
CA (1)	CA2333657A1 (de)
DE (1)	DE69930739D1 (de)
WO (1)	WO1999064059A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6020310A (en) *	1997-05-19	2000-02-01	Repligen Corporation	Method for assisting in differential diagnosis and treatment of autistic syndromes
US6197746B1 (en) *	1998-05-19	2001-03-06	Repligen Corporation	Method of using secretin for treating autism
US6020314A (en) *	1998-08-11	2000-02-01	Milkhaus Laboratory, Inc.	Methods for treatment of neurological disorders
AU1779301A (en) *	1999-11-22	2001-06-04	Joseph A. Rogoff	Secretin and secretin pharmaceuticals for treating attention deficit disorder
US6534063B1 (en)	1999-12-17	2003-03-18	Joan M. Fallon	Methods for treating pervasive development disorders
US6632429B1 (en)	1999-12-17	2003-10-14	Joan M. Fallon	Methods for treating pervasive development disorders
GB0008326D0 (en) *	2000-04-06	2000-05-24	Shs International Ltd	Diagnosis and treatment of autism and related disorders
GB0016441D0 (en)	2000-07-04	2000-08-23	Pharmagene Lab Limited	Therapeutic method
WO2002014537A2 (en) *	2000-08-14	2002-02-21	Fallon Joan M	Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) *	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
CA2419285C (en) *	2000-08-25	2011-08-02	Research Corporation Technologies, Inc.	New uses for amino acid anticonvulsants
US8030002B2 (en)	2000-11-16	2011-10-04	Curemark Llc	Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0118383D0 (en) *	2001-07-27	2001-09-19	Pharmagene Lab Ltd	Therapeutic methods
US6585996B1 (en)	2002-03-13	2003-07-01	Westlake Laboratories, Inc.	Lipid-soluble thiamine derivatives in the treatment of autism
US8100844B2 (en) *	2002-04-25	2012-01-24	Ultraflex Systems, Inc.	Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
WO2004080476A1 (en) *	2003-03-12	2004-09-23	University Of North Carolina At Chapel Hill	Use of secretin in the treatment of schizophrenia
US20050002922A1 (en) *	2003-03-12	2005-01-06	Richard Boismenu	Use of secretin and secretin analogs to treat affective disorders
WO2004100899A2 (en) *	2003-05-13	2004-11-25	The Mclean Hospital Corporation	Use of secretin in treatments of disorders associated with the amygdala
US7947285B2 (en) *	2003-12-12	2011-05-24	Fein Seymour H	Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US7381698B2 (en) *	2003-12-12	2008-06-03	Chirhoclin, Inc.	Methods for treatment of acute pancreatitis
US20060198838A1 (en) *	2004-09-28	2006-09-07	Fallon Joan M	Combination enzyme for cystic fibrosis
GB0504096D0 (en) *	2005-02-28	2005-04-06	Tipogen As	Method
US20070034214A1 (en) *	2005-08-12	2007-02-15	Dochniak Michael J	Method to affect the development of autism spectrum disorders
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
US20070116695A1 (en) *	2005-09-21	2007-05-24	Fallon Joan M	Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) *	2008-06-26	2016-04-26	Curemark Llc	Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) *	2008-06-26	2009-12-31	Fallon Joan M	Methods and compositions for the treatment of symptoms of complex regional pain syndrome
EP2318035B1 (de) *	2008-07-01	2019-06-12	Curemark, Llc	Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en) *	2008-08-04	2020-09-15	Galenagen, Llc	Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) *	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en)	2009-01-06	2015-07-21	Curelon Llc	Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
ES2668909T3 (es)	2009-01-06	2018-05-23	Galenagen, Llc	Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9056050B2 (en) *	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
EP2485744A4 (de) *	2009-10-09	2014-01-22	Prothera Inc	Zusammensetzungen und verfahren mit pediokokken zur reduzierung mindestens eines symptoms für autismusspektrumserkrankungen bei einem patienten mit diagnostizierter autismusspektrumserkrankung
US9511125B2 (en)	2009-10-21	2016-12-06	Curemark Llc	Methods and compositions for the treatment of influenza
JP5902148B2 (ja) *	2010-03-31	2016-04-13	アベラファーマスーティカルズインコーポレイテッド	自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤
US9931365B2 (en)	2010-09-28	2018-04-03	Lisa Geng	Methods for treating neurological disorders using nutrient compositions
US8962042B2 (en)	2010-09-28	2015-02-24	Lisa Geng	Methods for treating neurological disorders using nutrient compositions
CN106310242B (zh)	2011-04-21	2020-02-28	柯尔马克有限责任公司	用于治疗神经精神障碍的化合物
WO2012177647A2 (en)	2011-06-20	2012-12-27	Kerry Lane	Mycotoxin diagnostics and methods thereof
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
WO2018191233A1 (en)	2017-04-10	2018-10-18	Curemark, Llc	Compositions for treating addiction
US11318190B2 (en) *	2017-05-05	2022-05-03	United States Government As Represented By The Department Of Veterans Affairs	Methods and compositions for treating liver disease
CN109908120B (zh) *	2019-04-22	2022-04-19	井冈山大学	一种狭顶鳞毛蕨有效成分、提取方法及其应用
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3833722A (en)	1971-03-16	1974-09-03	D Graybill	Method for controlling allergies
JPS5029005B2 (de) *	1972-05-08	1975-09-19
US3987014A (en)	1974-01-10	1976-10-19	Becton, Dickinson And Company	Secretin intermediates and derivatives
DE2615229C2 (de)	1976-04-08	1984-05-24	Hoechst Ag, 6230 Frankfurt	Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en)	1976-08-09	1978-04-25	G. D. Searle & Co.	Fragments of secretin
EP0021184B1 (de)	1979-06-13	1984-02-08	Hoechst Aktiengesellschaft	Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
NZ196349A (en)	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja)	1982-02-15	1983-08-19	Eisai Co Ltd	セクレチンの精製方法
DE3328793A1 (de)	1983-08-10	1985-02-28	Hoechst Ag, 6230 Frankfurt	Herstellung von sekretin
SE454513B (sv)	1985-03-11	1988-05-09	Kabigen Ab	Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja)	1985-06-04	1986-12-08	Suntory Ltd	自閉症治療剤
US5008251A (en)	1986-03-27	1991-04-16	The Regents Of The University Of California	Method of treating autism
US4994467A (en)	1989-05-31	1991-02-19	Zimmerman Andrew W	Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en)	1990-01-22	1992-03-10	Wayne State University	Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en)	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
US5380872A (en) *	1992-07-14	1995-01-10	Glaxo Inc.	Modulators of cholecystokinin
EP0681491B1 (de)	1993-01-29	2000-12-13	Aradigm Corporation	Intrapulmonares hormonabgabesystem
US5527825A (en)	1994-04-06	1996-06-18	University Of Arkansas	Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
US5560910A (en) *	1994-08-26	1996-10-01	Crandall; Wilson T.	Topical anti-inflammatory composition and method
GB9417524D0 (en)	1994-08-31	1994-10-19	Cortecs Ltd	Pharmaceutical compositions
US5686311A (en)	1995-06-23	1997-11-11	The Children's Mercy Hospital	Diagnosis of autism and treatment therefor
US6020310A (en) *	1997-05-19	2000-02-01	Repligen Corporation	Method for assisting in differential diagnosis and treatment of autistic syndromes
US6197746B1 (en) *	1998-05-19	2001-03-06	Repligen Corporation	Method of using secretin for treating autism
CA2303484A1 (en)	1997-09-11	1999-03-18	The Regents Of The University Of California	Plus end-directed microtubule motor required for chromosome congression

1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 EP EP99927416A patent/EP1085901B1/de not_active Expired - Lifetime
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69930739D1 (de)	2006-05-18
US20010049353A1 (en)	2001-12-06
WO1999064059A3 (en)	2000-03-02
EP1085901B1 (de)	2006-04-05
US20050249714A1 (en)	2005-11-10
US6197746B1 (en)	2001-03-06
US6790825B2 (en)	2004-09-14
WO1999064059A2 (en)	1999-12-16
JP2002517467A (ja)	2002-06-18
EP1085901A2 (de)	2001-03-28
AU772911B2 (en)	2004-05-13
AU4432299A (en)	1999-12-30
CA2333657A1 (en)	1999-12-16

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE322283T1 (de)	2006-04-15	Transdermale verwendung von sekretin zur behandlung von autismus
DE69815122D1 (de)	2003-07-03	Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69713526D1 (de)	2002-07-25	Lösliche prodrugs von paclitaxel
ATE185268T1 (de)	1999-10-15	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
NO20053077L (no)	2005-09-22	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BR9813373A (pt)	2000-10-03	Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
DE60239612D1 (de)	2011-05-12	Monodisperse mischungen und verfahren zur behandlung von diabetes
RU2000130209A (ru)	2002-10-20	Новое применение
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69939705D1 (de)	2008-11-20	Behandlung der pompeschen krankheit
RU94027680A (ru)	1996-11-10	Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
MD960307A (ro)	1997-10-31	Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii
ATE144420T1 (de)	1996-11-15	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69403969D1 (de)	1997-07-31	Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE69914084D1 (de)	2004-02-12	Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
ATE93138T1 (de)	1993-09-15	Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE58901002D1 (de)	1992-04-30	Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR9813318A (pt)	2000-08-22	Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
IL192287A0 (en)	2008-12-29	Pharmaceutical compositions and methods for use
BR9908190A (pt)	2000-10-24	Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente
PT1231908E (pt)	2004-06-30	Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
RU95100951A (ru)	1997-06-10	Способ лечения мужского бесплодия
AR005724A1 (es)	1999-07-14	Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
DE69733321D1 (de)	2005-06-23	Olanzapine zur behandlung von drogenmissbrauch